Genelux (NASDAQ:GNLX) Insider Yong Yu Sells 9,683 Shares of Stock

Genelux Corporation (NASDAQ:GNLX) insider Yong Yu sold 9,683 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $2.75, for a total value of $26,628.25. Following the completion of the sale, the insider owned 258,688 shares in the company, valued at approximately $711,392. The trade was a 3.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Yong Yu also recently made the following trade(s):

• On Tuesday, August 4th, Yong Yu sold 653 shares of Genelux stock. The stock was sold at an average price of $2.94, for a total value of $1,919.82.

Genelux Price Performance

GNLX opened at $2.55 on Thursday. The business has a fifty day moving average price of $2.83 and a 200 day moving average price of $2.78. Genelux Corporation has a 12 month low of $2.29 and a 12 month high of $8.53. The stock has a market capitalization of $115.37 million, a price-to-earnings ratio of -2.97 and a beta of 0.57.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). On average, research analysts anticipate that Genelux Corporation will post -0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GNLX. Wall Street Zen raised shares of Genelux from a “strong sell” rating to a “sell” rating in a report on Sunday, August 23rd. Benchmark reiterated a “speculative buy” rating on shares of Genelux in a report on Tuesday, August 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. purchased a new position in shares of Genelux in the 1st quarter valued at about $239,000. Jane Street Group LLC acquired a new stake in shares of Genelux during the 1st quarter worth about $190,000. Geode Capital Management LLC lifted its stake in Genelux by 1.8% during the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after purchasing an additional 5,596 shares during the last quarter. Marshall Wace LLP purchased a new stake in Genelux during the second quarter worth approximately $92,000. Finally, Raymond James Financial Inc. lifted its stake in Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after purchasing an additional 5,333 shares during the last quarter. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.